Literature DB >> 24688111

The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Jo Caers1, Nadia Withofs, Jens Hillengass, Paolo Simoni, Elena Zamagni, Roland Hustinx, Yves Beguin.   

Abstract

Multiple myeloma is the second most common hematologic malignancy and occurs most commonly in elderly patients. Almost all multiple myeloma patients develop bone lesions in the course of their disease or have evidence of bone loss at initial diagnosis. Whole-body conventional radiography remains the gold standard in the diagnostic evaluation, but computed tomography, magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography are increasingly used as complementary techniques in the detection of bone lesions. Moreover, the number of lesions detected and the presence of extramedullary disease give strong prognostic information. These new techniques may help to assess treatment response in solitary plasmacytoma or in multiple myeloma. In this article, we review recent data on the different imaging techniques used at diagnosis and in the assessment of treatment response, and discuss some current issues.

Entities:  

Mesh:

Year:  2014        PMID: 24688111      PMCID: PMC3971072          DOI: 10.3324/haematol.2013.091918

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  59 in total

1.  Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?

Authors:  Andrea Baur; Axel Stäbler; Dorothea Nagel; Rolf Lamerz; Reiner Bartl; Erhard Hiller; Clemens Wendtner; Fridleif Bachner; Maximilian Reiser
Journal:  Cancer       Date:  2002-09-15       Impact factor: 6.860

2.  Whole-body (18)F-FDG PET identifies high-risk myeloma.

Authors:  Brian G M Durie; Alan D Waxman; Allesandro D'Agnolo; Cindy M Williams
Journal:  J Nucl Med       Date:  2002-11       Impact factor: 10.057

3.  Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Authors:  Sarah Waheed; Alan Mitchell; Saad Usmani; Joshua Epstein; Shmuel Yaccoby; Bijay Nair; Rudy van Hemert; Edgardo Angtuaco; Tracy Brown; Twyla Bartel; James McDonald; Elias Anaissie; Frits van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

4.  Initial results in the assessment of multiple myeloma using 18F-FDG PET.

Authors:  H Schirrmeister; M Bommer; A K Buck; S Müller; P Messer; D Bunjes; H Döhner; L Bergmann; S N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03       Impact factor: 9.236

5.  The radiological demonstration of osseous metastases. Experimental observations.

Authors:  G A Edelstyn; P J Gillespie; F S Grebbell
Journal:  Clin Radiol       Date:  1967-04       Impact factor: 2.350

6.  Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review.

Authors:  Josien C Regelink; Monique C Minnema; Evangelos Terpos; Marjolein H Kamphuis; Pieter G Raijmakers; Indra C Pieters-van den Bos; Ben G F Heggelman; Rutger-Jan Nievelstein; Rene H J Otten; Danielle van Lammeren-Venema; Josee M Zijlstra; Anne I J Arens; Jacky W de Rooy; Otto S Hoekstra; Reinier Raymakers; Pieter Sonneveld; Raymond W Ostelo; Sonja Zweegman
Journal:  Br J Haematol       Date:  2013-04-25       Impact factor: 6.998

7.  Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.

Authors:  Benjamin M Cherry; Neha Korde; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Marcia Mulquin; Diamond Zuchlinski; Mary Ann Yancey; Irina Maric; Katherine R Calvo; Raul Braylan; Maryalice Stetler-Stevenson; Constance Yuan; Prashant Tembhare; Adriana Zingone; Rene Costello; Mark J Roschewski; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2013-07-29

Review 8.  Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

Authors:  Brian G M Durie; Robert A Kyle; Andrew Belch; William Bensinger; Joan Blade; Mario Boccadoro; J Anthony Child; Raymond Comenzo; Ben Djulbegovic; Dorotea Fantl; Gosta Gahrton; Jean Luc Harousseau; Vania Hungria; Douglas Joshua; Heinz Ludwig; Jayesh Mehta; Angelina Rodrique Morales; Gareth Morgan; Amara Nouel; Martin Oken; Raymond Powles; David Roodman; Jesus San Miguel; Kazuyuki Shimizu; Seema Singhal; Bhawna Sirohi; Pieter Sonneveld; Guido Tricot; Brian Van Ness
Journal:  Hematol J       Date:  2003

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

Authors:  Saad Z Usmani; Alan Mitchell; Sarah Waheed; John Crowley; Antje Hoering; Nathan Petty; Tracy Brown; Twyla Bartel; Elias Anaissie; Frits van Rhee; Bart Barlogie
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

View more
  27 in total

1.  Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma.

Authors:  L Giaccone; L Brunello; M Festuccia; M Gilestro; E Maffini; F Ferrando; E Talamo; R Passera; M Boccadoro; P Omedè; B Bruno
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 2.  Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Authors:  A M Sherrod; P Hari; C A Mosse; R C Walker; R F Cornell
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

Review 3.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

4.  Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century.

Authors:  Janick Weberpals; Dianne Pulte; Lina Jansen; Sabine Luttmann; Bernd Holleczek; Alice Nennecke; Meike Ressing; Alexander Katalinic; Maximilian Merz; Hermann Brenner
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

Review 5.  Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.

Authors:  Gary A Ulaner; C Ola Landgren
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

Review 6.  The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

Authors:  Jo Caers; Carlos Fernández de Larrea; Xavier Leleu; Roy Heusschen; Niklas Zojer; Olivier Decaux; Efstathios Kastritis; Monique Minnema; Artur Jurczyszyn; Yves Beguin; Ralph Wäsch; Antonio Palumbo; Meletios Dimopoulos; Maria Victoria Mateos; Heinz Ludwig; Monika Engelhardt
Journal:  Oncologist       Date:  2016-02-26

7.  Innovations in treatment and response evaluation in multiple myeloma.

Authors:  Ruth Wester; Pieter Sonneveld
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

8.  Diagnostic performance of 18F-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study.

Authors:  Mohammad Abd Alkhalik Basha; Maged Abdel Gelil Hamed; Rania Refaat; Mohamad Zakarya AlAzzazy; Manar A Bessar; Elshaimaa Mohamed Mohamed; Ayman F Ahmed; Heba Fathy Tantawy; Khaled Mohamed Altaher; Ahmed Ali Obaya; Amira Hamed Mohamed Afifi
Journal:  Jpn J Radiol       Date:  2018-04-18       Impact factor: 2.374

Review 9.  Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports.

Authors:  J C Glasbey; F Arshad; L M Almond; B Vydianath; A Desai; D Gourevitch; S J Ford
Journal:  Ann R Coll Surg Engl       Date:  2018-04-25       Impact factor: 1.891

10.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.